Financially troubled PET developer Positron appears to be making progress with its revival plans. The Houston-based firm has received approval from the Japanese Ministry of Health & Welfare for its Posicam-HZ Series PET scanner. The Posicam scanners
Financially troubled PET developer Positron appears to be making progress with its revival plans. The Houston-based firm has received approval from the Japanese Ministry of Health & Welfare for its Posicam-HZ Series PET scanner. The Posicam scanners will be marketed and distributed in Japan exclusively by Imatron Japan, an independent distributor in which ultrafast CT developer Imatron maintains a 24% equity stake. Imatron, of South San Francisco, CA, took over as controlling shareholder in Positron earlier this year (SCAN 2/3/99).
Upon completion of an expected major third-party equity financing deal, Positron will be well positioned to take advantage of PET market opportunities in Japan and the U.S., said Imatron CEO Lewis Meyer. Imatron hopes that the 24 Japanese customers of Imatrons ultrafast CT scanner will be interested in utilizing PET and ultrafast CT as complementary imaging modalities.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.